"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."
This is HCP only content
Terumo Interventional Oncology Division presents Occlusafe, an occlusive micro-balloon.
Through Pressure Gradient Effect, Occlusafe as micro-balloon catheter, offers the ability to redistribute blood flow and access the microcirculation, leading to an increased accumulation of therapeutics into the target lesion with minimal off-target embolization. This may be associated with improved clinical outcomes in challenging lesions3.
Large lesions partially respond to current TACE treatment due to a poor uptake of embolic. Multiple or combined treatments are required to reach a complete response.
Through Pressure Gradient Effect, Balloon Occlusion with Occlusafe offers the ability to redistribute blood flow and access the microvascular circulation, leading to an increased accumulation of therapeutics into the target lesion1 with minimal off-target embolization2.
Balloon Occlusion with Occlusafe allows a better visualization for improved diagnosis and higher uptake of embolic into the target lesion1.
Terumo excellence in lesion access technology guarantees for a superb precision and accuracy in navigation through complex vessel anatomies.
Including connector part
Please quote above item reference codes when placing an order.
Note: Comparison is done between TACE performed with Occlusafe
micro-balloon catheter and TACE with a standard micro-catheter.
1. Irie Toshiyuki (2013): Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurementof balloon occlude arterial stump pressure. Cardiovasc Intervent Radiol. DOI: 10.1001/s00270-012-0476-z
2. Terumitsu Hasebe; Minimally Invasive Therapy & Allied Technologies. 2015 Apr;24(2):94-100. doi: 10.3109/13645706.2014.951657. Epub 2014 Sep 29. PubMed.
3. Hriotaka Arai: Hepatology Research (2015): Safety and efficacy of balloon-occluded trancatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma; 45. 663-666
4. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, Moriyama N, Okusaka T, Okada S, Ueno H. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176: 681-688 [PMID: 11222205 DOI: 10.2214/ajr.176.3.1760681]
5. Hayashi K, Ina H, Tezuka M, Okada Y, Irie T. Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients. Cardiovasc Intervent Radiol 2007; 30: 1144-1155 [PMID: 17909884 DOI: 10.1007/s00270-007-9169-4]
6. Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, Takayama H, Abe T, Sato K, Kakizaki S, Yamada M. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study. Hepatol Res 2018; 48: 165-175 [PMID: 28500686 DOI: 10.1111/hepr.12912]
Data on files. Reference OS-003. Terumo Europe NV.
Our sales representatives are here for you
Radifocus® Guidewire M Non-Vascular
Radifocus® Introducer II Radiopaque Marker Kit C
Radifocus® Guidewire M Shapeable Type
Didn't find your product?